MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
57.69
+0.56
+0.98%
Pre Market: 58.82 +1.13 +1.96% 04:04 12/05 EST
OPEN
56.90
PREV CLOSE
57.13
HIGH
57.86
LOW
54.75
VOLUME
85
TURNOVER
0
52 WEEK HIGH
66.92
52 WEEK LOW
6.48
MARKET CAP
1.17B
P/E (TTM)
-7.2781
1D
5D
1M
3M
1Y
5Y
1D
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close
Seeking Alpha · 15h ago
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 3d ago
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
NASDAQ · 3d ago
Weekly Report: what happened at NKTR last week (1124-1128)?
Weekly Report · 4d ago
Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts
TipRanks · 6d ago
Citigroup Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation
NASDAQ · 11/26 23:53
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation
NASDAQ · 11/26 23:53
Nektar Therapeutics Initiated at Buy by Citigroup
Dow Jones · 11/26 19:26
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.